1. Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease.
- Author
-
Lian, Xinyue, Ye, Yan, Zou, Jing, Wu, Chunmei, Ye, Shuang, Guo, Qiang, Chen, Sheng, Lu, Liangjing, Wang, Ran, Fu, Qiong, and Bao, Chunde
- Subjects
AUTOANTIBODIES ,BIOMARKERS ,PATIENT aftercare ,DERMATOMYOSITIS ,MELANOMA ,ANTI-inflammatory agents ,INTERSTITIAL lung diseases ,FIBROSIS ,DESCRIPTIVE statistics ,PULMONARY function tests ,RESEARCH funding ,COMPUTED tomography ,PHENOTYPES ,LONGITUDINAL method ,DISEASE complications - Abstract
Objectives To describe the 8-year longitudinal study and long-term prognosis of a large inception cohort of anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive (MDA5+) DM-interstitial lung disease (ILD) patients. Methods In total, 216 patients diagnosed with MDA5+ DM-ILD were enrolled and followed up to analyse long-term survival rate. Demographic and clinical variables were collected at baseline and each temporal end point. Seventy patients who survived the first year were analysed for the long-term serological and respiratory outcomes. Results A total of 85 patients (39.3%) died during the follow-up period up to 96 months, with 89% of the deaths occurring in the first year after diagnosis. Long-term outcome was reported in 70 patients. Serological markers including anti-MDA5 antibody showed significant improvement with time. Radiographic findings and pulmonary function also improved notably in the follow-up period, especially in rapidly progressive ILD group, as measured by high-resolution computed tomography imaging scores, the estimated forced vital capacity, estimated diffusing capacity of lung carbon monoxide and dyspnoea scores. Early application of anti-fibrosis therapy helped to improve long-term pulmonary function. Conclusions MDA5+ DM-ILD patients had a high mortality rate despite aggressive treatment. Patients who survived the first year usually showed a significant improvement in serological markers and pulmonary function during the long-term follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF